{"podcast":{"title":"Business Of Biotech","slug":"business-of-biotech-123501","podcast_index_feed_id":123501,"rss_url":"https://rss.buzzsprout.com/1011661.rss","website_url":"https://www.bioprocessonline.com/solution/the-business-of-biotech-podcast","image_url":"https://storage.buzzsprout.com/35u0bccu9j9xpr9zrrjias54otax?.jpg","author":"Ben Comer","episode_count":310,"summary":"The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.","last_synced_at":"2026-06-08T22:18:30.179389+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501"},"episode":{"title":"Making Biologics Orally Available With Vivtex's Thomas von Erlach, Ph.D.","slug":"making-biologics-orally-available-with-vivtex-s-thomas-von-erlach-ph-d","published_at":"2026-03-02T11:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/making-biologics-orally-available-with-vivtex-s-thomas-von-erlach-ph-d","show_page_url":"https://stenobird.com/podcast/business-of-biotech-123501","url":"https://www.buzzsprout.com/1011661/episodes/18746013-making-biologics-orally-available-with-vivtex-s-thomas-von-erlach-ph-d.mp3","audio_url":"https://www.buzzsprout.com/1011661/episodes/18746013-making-biologics-orally-available-with-vivtex-s-thomas-von-erlach-ph-d.mp3","summary":"We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we're speaking with Thomas von Erlach, Ph.D., Cofounder and CEO at Vivtex, a company spun out of the Langer Lab at MIT that's focused on developing orally available biologics. The company announced a deal in late February '26 with Novo Nordisk for up to $2.1 billion to develop next-gen oral drugs for obesity and diabetes, bringing the total number of Vivtex's partnerships to 10. Thomas s...","meta_description":"We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we're speaking with Thomas von Erlach, Ph.D., Co…","key_points":[],"chapters":[],"topics":[],"duration_seconds":3237,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/making-biologics-orally-available-with-vivtex-s-thomas-von-erlach-ph-d/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/making-biologics-orally-available-with-vivtex-s-thomas-von-erlach-ph-d.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}